{
  "doc_id": "HTA_submission_sotosorib_PO",
  "created_date": "2023",
  "country": "PO",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Recommendation No 41/Lumykras Lumykras (sotorasib) drug drug program",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Reason for recommendation",
      "text": "cancer cancer (NDRP) gene gene (oncogene oncogene homolog) __MEDTERM0_ __MEDTERM0_ (2023 2023 v2).",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Subject matter",
      "text": "medicinal medicinal product: • GTIN GTIN code: sales sales price: ; patients patients (ICD-10: C34) mesothelioma mesothelioma (ICT-10:C45).",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Health problem",
      "text": "cancer cancer (ICD-10 ICD-10 classification) bronchi bronchi (respiratory tract) of of histology: • gland cancer (45% - recent recent period); • carcinoma carcinoma (30%); • carcinoma carcinoma (15%); − carcinoma carcinoma (10%). cancers cancers (DRP) conditions conditions (respectively. respectively.",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Alternative medical technology",
      "text": "with with docetaxel; patients patients (ICD-10: C34) mesothelioma mesothelioma (IC D-10:C45), process. process.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "applied applied for",
      "text": "__MEDTERM0_ __MEDTERM0_ (sarcoma sarcoma Kirsten), factor factor (ChPL) cancer cancer (NDRP) bitherapy bitherapy (IQR1): First analysis (_MEDTERM10_): 7,1 (3,8.11); Final Analysis (_medTERM11_): endpoints endpoints (PK) studies studies are: • Progression-free survival (_MEDTERM10__) Module Module () cancer cancer (chest chest pain). condition condition • No No 41/g. g.: • overall survival, • response response • treatment treatment lines: DOC DOC 40% vs 17% OR (95% CI) = 3.10 (1.39; 6.92) • ECOG ECOG 0: DOC DOC 34% vs 14% OR (95%CI) = 4.02 (1.44; 11.17 • ECOG ECOG 1: median median (95% CI): 2.16 (1.07; 4.34) • metastatic metastatic SOT/doc 28% vs 10% OR (95% Ci) = 3.33 (1.20; 9.28) 3. 3.1% 69 69 (95% volt.1 (1.30 (1.17; 4.51) − liver liver metastasy: SOT SOT (1.12; 9.28) 3. 3.1% (following following table: (5,9; 8,9); at at ≥months. months. (8. 8.9). of of performance: • ECOG 0-1 (Julve 2021 72%, ECOG ECOG 1: 13%, ECOG 1.1%, ECOG ECOG 2: 17%; ECOG 3:2%) ECOG ECOG = 20%, ECog 1: 61%), events events ≥treatment treatment (TEAE), in in ≥10% associated associated with: • diarrhoea diarrhoea (total and ≥3 grade), AST AST increased; •neutropenia neutropenia (absolute and ≥3) neuropathy neuropathy (1 AES) reported in ≥ 10% general, general, 23% in in 7% in in 26% of patients; in in 1% (to to pneumonia) in in 26%. common common (≥ 10% of patients) reactions reactions (≥ 1/10) sick sick (vomiting), aminotransferase. aminotransferase.",
      "start_page": 3,
      "end_page": 10
    },
    {
      "heading": "sharing sharing instruments",
      "text": "life life (years years gained) health health (life life years) therapy therapy (vs vs NIN+utility utility (ICUR) NFZ NFZ was: • docetaxel docetaxel (DOC): • docetaxel docetaxel [NIN+doc]: − pemetrexed pemetrexed (PMX): the the applicant'platinum platinum (P-CTH) shall shall be: zł zł (cisplatin cisplatin + paclitaxel) zł zł (1c). public public payer'the the patient'public public payer'by by approximately: • year, year, • among among others: function. function.",
      "start_page": 10,
      "end_page": 13
    },
    {
      "heading": "drug drug programme",
      "text": "the the patient'chemotherapy chemotherapy (docetaxel or pemetrexed), generation, generation, inhibitors/immunotherapy immunotherapy (_MEDTERM3_ or __METERM4_), recommendations recommendations (G-Ba G-Ba 2022), limitation limitation (GA GA 2022), recommendation recommendation (PBAC 2022).",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "of of recommendations",
      "text": "Health Health (sign:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "• GTIN GTIN code: 08715131024895,",
      "text": "program program \"Lung cancer treatment\" (ICD-10: C34) and \"Pleural mesothelioma\" (ICT-10:C45) '; 35 35 (1) devices devices (as as amended), No No 41/Lumykras Lumykras (sotorasibum) programme programme \"Lungs cancer medicine\" (ICD-10: c34) pleural pleural (IC D-10:c45)",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Writing",
      "text": "No No 41/Lumykras Lumykras (sotorasibum) drug drug program",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heading heading <Health problem>",
      "text": "Row 1: - Row 2: - Row 1:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <risk-sharing risk-sharing instruments>",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "heading heading <sharing sharing instruments> (from previous page)",
      "text": "Row 1: - Row 2: - Row 1:",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <drug drug programme>",
      "text": "Row 1: - Row 2: - Row 1:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <drug drug programme>",
      "text": "Row 1: . .. Row 2: .. and Row 3: .. . . Row 4: .. row 5: ..",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <drug drug programme> (from previous page)",
      "text": "Row 1: * Row 2: * Row 3: *",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <drug drug programme> (from previous page)",
      "text": "Row 1: Row 2:",
      "start_page": 14,
      "end_page": 14
    }
  ]
}